- Virtual poster presentation shows complete tumor regression and high tolerability of a SYNtecan E™ based ADC
- SYNtecan E™ linker-payload is a potent exatecan-based, DNA topoisomerase 1 inhibitor developed by Synaffix
- Data underscores ability of Synaffix’s technologies to enable best in class, next generation ADCs
AMSTERDAM, NETHERLANDS, 13th October 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index will present new data regarding its topoisomerase 1 inhibitor linker-payload based on exatecan (SYNtecan E™), at the World ADC Conference on 13 October 2021:
- Title: GlycoConnect™ ADCs Based on Topoisomerase 1 Inhibitor Exatecan (SYNtecan E™) Show Excellent In Vivo Efficacy and Tolerability
- Time: 9:30pm CEST / 3:30pm EDT / 12:30 PDT
- Authors: Floris van Delft, Remon van Geel, Jorin Hoogenboom, Marloes Wijdeven, Laureen de Bever, Sorraya Popal, Jord van Schaik, Sander van Berkel
Synaffix utilizes GlycoConnect™, a proprietary technology based on the native glycan of monoclonal antibodies, which is used as a privileged conjugation site for ADCs. In addition, a highly polar spacer technology (HydraSpace™) enables the conjugation of any cytotoxic, hydrophobic payload, providing ADCs with significantly expanded therapeutic index (TI).
Camptothecins form a class of clinically relevant chemotherapy drugs based on their ability to inhibit DNA topoisomerase 1 while also demonstrating excellent potential as payloads for antibody-drug conjugates (ADCs), as exemplified by the recent market approvals of Enhertu® and Trodelvy®.
Synaffix’s data demonstrate that:
- Exatecan, a clinically validated and potent campothecin, is readily combined with Synaffix’s HydraSpace™ technology, resulting in the SYNtecan E™ linker-payload
- GlycoConnect™ ADCs of trastuzumab were generated by conjugation of SYNtecan E™ to antibodies and evaluated for efficacy and tolerability
- Complete tumor regression was observed in a mouse xenograft study (BT-474) after a single dose, while safety studies in mice corroborated high tolerability of SYNtecan E™ ADCs
Prof. Floris van Delft, CSO of Synaffix, said: “We are delighted to be presenting new data on our groundbreaking technologies at this distinguished annual meeting. As the ADC community once again comes together to share its latest research, Synaffix is excited to showcase its continued efforts to develop truly best-in-class ADC therapeutics.”
In the last few months, Synaffix has signed significant ADC technology out-licensing agreements with Kyowa Kirin, a global specialty pharmaceutical company; ProfoundBio, an emerging oncology biotherapeutics company; and Innovent Biologics, a leading biopharmaceutical company developing innovative medicines for the treatment of major diseases. These come in addition to earlier collaborations with ADC Therapeutics, Mersana Therapeutics and Shanghai Miracogen. Three ADCs using Synaffix’s technology are in the clinic.
